Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-to-Lot Consistency of Three Lots of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Adults Aged 18 to 45 Years

NCT04786444 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT04786444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04786444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-to-Lot Consistency of Three Lots of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Adults Aged 18 to 45 Years
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
February 22, 2021
Completion date
January 26, 2022
Enrollment
409 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection